ARE YOU A RESEARCHER AT A HCC MEMBER INSTITUTION?LEARN HOW TO BECOME A MEMBER

New Members

Latest News and Announcements

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Shah K, Anastasakou E, Sejour L, Guseva S, Rauchet C, Wert-Lamas L, Calandrelli R, Distel R, Zhong S, Vlachos I, Novina CD. Long non-coding RNA triplex-dependent regulation of melanoma gene networks. NAR Genom Bioinform 2026; 8:lqag067. PubMed
  • Tarantino P, Li T, Ogayo ER, Rahman T, DiLullo MK, Patel A, El-Refai S, Abbott C, Li B, Boyle SM, Chen RO, Desai NV, Spring LM, Tung NM, Sinclair N, Faggen M, Constantine M, King TA, Krop IE, Tayob N, Mittendorf EA, Tolaney SM, Winer EP, Parsons HA, Waks AG. Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe Trial. JAMA Oncol 2026. PubMed
  • Tanu T, Cox AM, Karlow JA, Sharma P, Sun K, He X, Babu S, Roelofs MK, Jeon E, Chen J, Wu C, Brown J, Barrientos NB, McCallion AS, Brown KM, Chanock SJ, Liu D, Zhang T, Burns KH, Boutz PL, Insco ML. Recurrent ZC3H18 mutations stabilize oncogenic endogenous retroviral RNA. Cell Rep 2026; 45:117526. PubMed
  • Wright SJ, Zamora I, Parikh M, Yeramosu D, Rucevic M, Sade-Feldman M, LaSalle TJ, Blaum EM, Liu B, Bi L, Kang S, Blum SM, Nguyen N, Guess J, Kar A, Schneider AM, Lieb D, Woods E, Michaud W, Lawless AR, Sharova T, Cohen S, Kasumova G, Kim MS, Cheng LC, Villani AC, Park RJ, Jenkins RW, Klempner SJ, Sullivan RJ, Flaherty KT, Hacohen N, Mehta A, Boland GM. Multimodal blood based proteomic profiling reveals insights into mechanisms of immunotherapy resistance. Nat Commun 2026. PubMed
  • Gonzalez Castro LN, Wu YC, Lin JR, Santiago-Ribeiro MJ, Laurenge A, Carpentier A, Coy S, Lin NU, Mokhtari K, Ligon KL, Touat M, Santagata S. Clinical responses to trastuzumab deruxtecan in molecularly defined ependymoma. NPJ Precis Oncol 2026. PubMed
  • Ge Y, de Almeida Magalhaes T, Wu H, van den Boomen DJH, Nguyen TU, Dou T, Yadav GP, Lee S, Wang Z, Lemoff A, Luo X, Menon SS, Zhang M, Wang J, Jin Z, Jiang J, Salic A, Huang P. Conformational cycling of the Wntless transporter drives trafficking and secretion of Wnt morphogens. Nat Commun 2026. PubMed
  • Hirayama S, Al-Inaya Y, Bryan ME, Das D, Aye L, Naegele S, Mendel J, Faquin WC, Sadow PM, Crowson MG, Lin D, Varvares M, Feng AL, Deschler D, Paly J, Merkin R, Roberts TJ, Lawrence M, Iafrate AJ, Wirth L, Fisch AS, Guan Z, Richmon J, Faden DL. Clinical validation of an HPV whole-genome sequencing assay for MRD detection in patients with HPV+ head and neck cancer treated with surgery. Sci Transl Med 2026; 18:eaec1724. PubMed
  • Simonet NG, Thackray JK, Kesner B, Guitart-Solanes A, Serra F, Espinosa-Alcantud M, Lappala A, Marín-Gual L, Marín-García C, Weissbein U, Castelló-García J, Bauer M, Wang D, Rovirosa L, Tischfield J, Serrano L, Payer B, Ruiz-Herrera A, Vazquez BN, Javierre BM, Vaquero A, Lee JT. SIRT7 regulates dosage compensation and safeguards the female X chromosome. Nature 2026. PubMed
  • Perez D, Breglio KF, Knox KM, Pereira AC, Gaziano JM, Wheless LE, Hartman RI. Cost-Effectiveness of Oral Nicotinamide for Keratinocyte Carcinoma Prevention. JAMA Dermatol 2026. PubMed
  • Jia Y, Sun D, Weir JA, Liu X, Russell AJC, Kim Y, Thom N, Marrero G, Kumar V, Chen F, Camargo FD. SPACE-seq integrates spatial transcriptomics and lineage tracing in native tissues. Cell Stem Cell 2026. PubMed
  • Johnson KC, Spitzer A, Varn FS, Nomura M, Garofano L, Chowdhury T, Lipsa A, Zhang L, Fernández EC, Barak T, Gulhan Ercan-Sencicek A, Peksen AB, Anderson KJ, Tesileanu CMS, Amin SB, Kocakavuk E, Zhao D, D'Angelo F, Migliozzi S, Bussema L, Gritsch S, Moon HE, Paek SH, Bielle F, Laurenge A, Di Stefano AL, Mathon B, Picca A, Sanson M, Hau AC, Hertel F, Grzyb K, Zhao Z, Wang Q, Jiang T, Miller JJ, Wakimoto H, Cahill DP, Moliterno J, Günel M, Hermes B, Sanai N, Golebiewska A, Niclou SP, Huse J, Alfred Yung WK, Lasorella A, Suvà ML, Iavarone A, Tirosh I, Verhaak RGW. Acquired genetic and cell-state changes in IDH-mutant glioma progression. Nature 2026. PubMed
  • Wei Y, Corchete Sánchez LA, Mathavarajah S, Antelo D, Wang S, Lee J, Weissman AD, Kannambadi DD, Qin Q, Danielli SG, Quantin EJ, Eng TC, Veloso A, Wang Y, Neilsen GP, Yan C, Yang VS, Patel AG, Koo SC, Odeniyide P, Pratilas CA, Rivera MN, Rheinbay E, Langenau DM. MYOD1 mutation drives cancer stem cell pathways and therapy-resistance in spindle cell/sclerosing rhabdomyosarcoma. Nat Commun 2026. PubMed
  • Smoragiewicz M, Bernard-Tessier A, Linch M, Shen J, Shore ND, Parikh O, Chi KN, Sokolova AO, Culine S, McKean M, Gleave M, Devitt ME, Zhi E, Gong J, Landrette S, Colasanto M, Patel V, Gao X. Phase 1b trial of Bavdegalutamide (ARV-110) in combination with Abiraterone for metastatic prostate cancer. Clin Cancer Res 2026. PubMed
  • Ghannam JY, Bryan J, Weiss J, Kovarsky D, Merrell D, Messer C, Schlueter-Kuck K, Fell GG, Lim-Fat MJ, Youssef G, Rahman R, Qin L, Young GS, Janes JT, Van Orden M, Pfaff KL, Gans A, Lin ES, Huang RY, Danysh BP, Parida L, Li S, Wen PY, Chiocca EA, Neuberg D, Ligon KL, Tirosh I, Reardon DA, Getz G, Wu CJ. Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma. Nat Cancer 2026; 7:964-982. PubMed
  • Cheruiyot CK, Kim SY, Dubrot J, Lane-Reticker SK, Miranda A, Kammula AV, Perera JJ, Du PP, Chuong CL, Fetterman RA, Knudsen NH, Jiang A, Suermondt JSMT, Pass LF, Fu C, Wu MJ, Shi L, Anderson S, Muscato AJ, Avila OI, Kohnle IC, Kessler EA, Pope HW, Noel SG, Olander KE, Chung J, Colvin KJ, Bardeesy N, Yates KB, Manguso RT. Inflammatory cytokines induce new cancer dependencies. Nat Genet 2026; 58:1353-1367. PubMed
  • Taplin ME, Gleave M, Shore ND, Lopez-Gitlitz A, Kretschmer A, Efstathiou E, Nguyen PL, Damião R, Kamoto T, Ross A, Briganti A, Hadaschik BA, Heidenreich A, Juárez Soto Á, Ye H, Gotto G, Rooney B, Tian SK, Wetherhold L, Miladinovic B, McCarthy SA, Evans CP, Kibel AS, . Perioperative Apalutamide in High-Risk Localized Prostate Cancer. N Engl J Med 2026. PubMed
  • O'Reilly EM, Wainberg ZA, Hendifar AE, Borad MJ, Pietrantonio F, Pant S, Hammel P, Cremolini C, Manji GA, Oberstein PE, Garrido-Laguna I, Springfeld C, Azad NS, Ueno M, Chui SY, Zhang Y, Patel H, Lee Y, Salman Z, Wolpin BM, . Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. N Engl J Med 2026. PubMed
  • Agius MP, Song C, Liu Q, Iemura T, Hevenor L, Payne NC, Pistofidis RS, Pantano L, Zhao H, Seo HS, Heilpern-Mallory D, Heaslip C, Sun ZJ, Bashyal P, Aranha MP, Lightbody E, Mazitschek R, Dhe-Paganon S, Mitsiades CS, Ghobrial IM, Qi J. Pharmacological targeting of IRF4 as a therapeutic strategy for multiple myeloma. Nat Chem Biol 2026. PubMed
  • Pagani O, Niman SM, Ruggeri M, Peccatori FA, Azim HA, Colleoni M, Saura C, Shimizu C, Sætersdal AB, Kroep JR, Warner E, Amant F, Mailliez A, Moore HCF, Ruiz-Borrego M, Walshe JM, Borges VF, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Saunders C, Bjelic-Radisic V, Susnjar S, Cardoso F, Klar NJ, Ferreiro T, Ribi K, Ruddy KJ, Kammler R, El-Abed S, Viale G, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Partridge AH, , . Updated Results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) Trial. Ann. Oncol. 2026. PubMed
  • Ummarino S, Poluben L, Ebralidze AK, Autiero I, Rinaldi L, Paniza T, Deshpande M, Mandel NH, Lee JD, Zhang Y, Bassal MA, Budnik B, Trinh BQ, Balk SP, Flaumenhaft R, Gerhardt J, Mirkin SM, Tenen DG, Di Ruscio A. RNAs anchoring replication complex control initiation and firing of DNA replication. Nat Commun 2026. PubMed
  • Nogal A, Wang K, Thompson KN, Kim H, Bhosle A, Piccinno G, Maharjan S, Upreti C, Nguyen LH, Segata N, Rimm EB, Garrett WS, Chan AT, Huttenhower C, Song M. Long-lasting gut microbiome and fecal metabolome alterations after colorectal adenoma removal and their relationship to colorectal cancer. Cell Host Microbe 2026. PubMed
  • Sperling AS, Derman BA, Nikiforow S, Alonso A, Ikegawa S, Orwitz N, Quinn DS, Pearson D, Bu D, Milanez-Almeida P, Mataraza J, Nadeem O, Liegel J, D'Souza A, Charles A, Credi M, Ritz J, Jakubowiak AJ, De Vita S, Munshi NC. Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma. Sci Transl Med 2026; 18:eadx1799. PubMed
  • Chen EC, Liu Y, Bell HL, Ryan J, Wu J, Minihane EJ, Luskin MR, Winer ES, Vedula R, Volpe V, Stahl M, Roberts D, Galinsky I, Gerard M, Hersch M, Lee J, Neuberg D, Stone RM, DeAngelo DJ, Letai A, Lane AA, Garcia JS. Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A phase 1 dose-escalation study of Navitoclax, Venetoclax, and Decitabine. Clin Cancer Res 2026. PubMed
  • Lobel L, Fonseca-Pereira D, Nakatsu G, Michaud M, Cao YG, Bae S, Krabak C, Oren Y, Clay SL, El Tekle G, Chun E, Kon S, Chan AT, Clardy J, Glickman JN, Ajami NJ, Day A, Damania A, Baruch EN, White MG, Diggs LP, Wargo J, Riffelmacher T, Balancio A, Kronenberg M, Huttenhower C, Garrett WS. Dietary sulfur amino acids enhance anti-tumor immunity in colon cancer via an NKT cell-XCL1-cDC1 circuit. Immunity 2026. PubMed
  • Merriam P, Morrow JJ, Mazzola E, Solimini NL, Gokhale PC, Chi P, Chen AP, Agulnik M, Burgess M, Schuetze SM, Somaiah N, Van Tine BA, Pollack SM, Tinoco G, Trent J, Wilky BA, Bothwick N, Eschle BK, Nguyen V, Beumer JH, Rastkari N, Jiwani S, Wu PI, Pelosof L, Hemming ML, Shapiro GI, Demetri G, Bernstein B, George S. Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial. Nat Med 2026. PubMed
  • Wong AYL, Myers JW, Prakash G, Ma A, Brook JR, Petrova B, Bulut B, White R, Merz C, de Souza M, Maynard AG, Wang P, Yu A, Pohl NK, Weitman M, Silverman LB, Stegmaier K, Churchman LS, Cole PD, Brady DC, Kanarek N. Copper depletion boosts CNS leukemia therapy by inhibiting nucleotide synthesis through impairment of mitochondrial complex IV activity. Nat Cancer 2026. PubMed
  • Singh PN, Hadj Bachir E, Howe JR, Bellizzi AM, Cejas P, Madha-Krause S, Epstein CB, Chan J, Bernstein BE, Kulke MH, Zhou Q, Shivdasani RA. Multiomic analyses delineate human neuroendocrine tumor cell states in relation to normal enteroendocrine cell ontogeny. J Clin Invest 2026. PubMed
  • Sun W, Patil A, Vicent MA, Montagnese B, Zielke J, Hefferman GM, Pan I, Cleaver G, Eldaief MC, Patel R, Mendoza-Millan DL, Landry J, Moreno-Lizarazo O, Odukoya OA, Johnston BR, Huang KT, Arnaout O. Patient-friendly simplification and translation of neuroradiology impressions using artificial intelligence. Sci Rep 2026. PubMed
  • Dong H, Ray A, Rotter LK, Wang J, Grabski I, Mewada H, Wang L, Huang K, Tian Y, Meylan M, Barlow G, Yu C, Raundhal M, Yoon SH, Nakhawa S, Ding L, Zhao JJ, Matulonis UA, Foretz M, Wucherpfennig KW, Irizarry RA, Wein MN, Glimcher LH. Inhibition of salt-inducible kinases reprograms T cells and antitumor immunity in ovarian cancer. Nat Immunol 2026. PubMed
  • Ehret F, Horick NK, Yeap BY, Curry WT, Nahed B, Daartz J, Johnson JM, Dagher SA, Raza SM, DeMonte F, Yeboa DN, Swanson TA, McAleer MF, Leland P, McGovern SL, Shih HA. Dose Escalation With Intensity-Modulated Proton Therapy for Patients with High-Risk Meningiomas - Results From a Phase 1 Trial. Clin Cancer Res 2026. PubMed
  • Sweis RF, Long GV, Daud A, Stemmer SM, Jimeno A, Perets R, Kummar S, Patel MR, Khattak A, Abadier M, Van L, Guo R, Do KT, Sullivan RJ. Lipid Nanoparticle-encapsulated mRNA-2752 Encoding Human OX40L, IL-23, and IL-36γ Plus Durvalumab Induces an Immunostimulatory Effect Within the Tumor Microenvironment in Patients with Advanced Solid Tumors. Clin Cancer Res 2026. PubMed
  • Garrido-Castro AC, Graham N, Li KX, Bi L, Crowdis J, Bi K, Park J, Pastorello R, Li Y, Gupta H, Kuntz T, Petry R, Pasquina LW, Patel A, Lange P, DiLullo M, Attaya V, Frey AM, Childress MA, Wesolowski R, Sinclair N, Sinclair S, Lo S, Tung N, Faggen M, Kaufman PA, Block CC, Walsh J, Toke M, Chen W, Wucherpfennig KW, Tian Y, Williams AJ, Mukhopadhyay S, Dasgupta T, Schnitt S, Cherniack AD, Barroso R, Ligibel J, Lin NU, Mittendorf EA, Tayob N, Van Allen E, Tolaney SM. Carboplatin with or without nivolumab in metastatic triple-negative breast cancer: a randomized phase II trial. Nat Commun 2026. PubMed
  • Algov I, Van Heest A, Hopton M, Liang F, Holmes A, Hao L, Zhou X. Proteolysis activity mapping and substrate discovery platform for identifying tumor-activated biosensors. Nat Chem Biol 2026. PubMed
  • Bourgeois W, Rice HE, Wenge DV, Perner F, Yue H, Regalado BD, Wan G, Schroeder JC, Sommerschield A, Hatton C, Singh S, Singh S, Bijpuria S, McKeever BM, Miller WH, Safer JF, Iqbal S, Perry JA, Fischer ES, Doench JG, McGeehan GM, Cutler JA, Armstrong SA. CRISPR base editor screening identifies spectrum of MEN1 mutations impacting menin inhibitors in clinical trials. Nat Commun 2026. PubMed
  • Hanna GJ, Zandberg DP, Wong DJ, Sherman E, Sacco AG, Yilmaz E, Hernando-Calvo A, Reiners RD, Bohr D, Salazar RL, O'Connell BC, Raben D, Schulten J, Chung CH, Kaczmar J. Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial. J Clin Oncol 2026. PubMed
  • Saad MA, Allen D, Sweeney A, Xavierselvan M, Mallidi S, Hasan T. Contrasting temporal dynamics of fluorescence and photoacoustic signals from Cetuximab-IRDye800 conjugate in EGFR-overexpressing tumors. Sci Adv 2026; 12:eadv4639. PubMed
  • Hanna GJ, Gupta TR, Trippa L, Rettig EM, Margalit DN, Tishler RB, Pashtan I, Kim E, Droznin A, Gunasti L, Maddox R, Minken J, Mukundan D, Sehgal K, Dennis MJ, O'Connor T, Qian JM, Boyd GH, Saraf A, Massiel Gil D, Sethi RK, Annino DJ, Goguen LA, Guenette JP, Bakhtiar M, Jo VY, Wong K, Uppaluri R, Haddad RI, Schoenfeld JD. Risk-adapted therapy guided by human papillomavirus (HPV) circulating tumor DNA in HPV-positive oropharyngeal cancer (ReACT 1.0): an exploratory phase II trial. Nat Commun 2026. PubMed
  • Wolpin BM, Park W, Garrido-Laguna I, Spira A, Starodub A, Sommerhalder D, Punekar SR, Barve M, Pelster M, Herzberg B, Azad NS, Hecht JR, Ou SHI, Lin T, Kar S, Tao L, Vora R, Hegde A, Aung K, Hong DS, . Daraxonrasib in Previously Treated Advanced -Mutated Pancreatic Cancer. N Engl J Med 2026; 394:1790-1802. PubMed
  • Stopfer JE, Horiguchi M, Chittenden A, Tso CG, Cahill SR, Buehler RM, D'Atri AK, Garber JE, Rana HQ. Video Education With Clinical Genetic Testing Coordinators for the Evaluation of Patients With Cancers: Real-World Evidence. JCO Oncol Pract 2026. PubMed
  • Foidart P, Li Z, Cai X, Seehawer M, Brown DD, Tawawalla A, Baldominos P, Parvin S, Nishida J, Rojas-Jimenez E, Bui TM, Diciaccio B, Kumar R, Schlegel BT, Goyette MA, Scales T, Yan P, Qiu X, Li R, Jiang Y, Xie Y, Aarabi M, Huang XY, Stevens LE, Cejas P, Mangiante L, Sotomayor Vivas CI, Houlahan KE, Curtis C, Oesterreich S, Harris IS, Letai AG, Lee AV, Long HW, Agudo J, Polyak K. Whole-genome doubling drives immune evasion by silencing antigen presentation. Cancer Cell 2026. PubMed
  • Cheek D, Blohmer M, Nowak MA, Antal T, Naxerova K. Age distinguishes selection from causation in cancer genomes. Nat Genet 2026. PubMed
  • Cheng X, Zhang Y, Qian C, Holdridge E, Ananda G, Jiang T, Ni J, Xie S, Gu H, Ji R, Ivanova EV, Nucci MR, Wang Z, Chen K, Kochupurakkal B, Freeman GJ, Shapiro GI, Liu J, Konstantinopoulos PA, Matulonis U, Zhao JJ. Targeting FGFR signaling overcomes therapeutic resistance and immune evasion in oncogenic PIK3CA-driven serous-like endometrial cancer. Nat Commun 2026. PubMed
  • Li Z, Fu C, Sehgal K, Egloff AM, Thai TC, Monge OA, Chuong CL, Senent Y, Lineberry MS, Eschle BK, Haratani K, Ivanova EV, Campisi M, Mahadevan NR, Quadarella JD, Gedeon PC, Schoenfeld JD, Kono M, Fahey CG, Chayawatto C, Ngo K, Paweletz CP, Gokhale PC, Manguso RT, Uppaluri R, Barbie DA. PTPN2 inhibition unleashes response to STING agonism in head and neck squamous cell cancer. Nat Commun 2026. PubMed
  • Lyu P, Agarwal G, Guo CJ, Sychla A, Bourgeois W, Ye T, Weng C, Antoszewski M, Joubran S, Caulier A, Poeschla M, Armstrong SA, Rouskin S, Sankaran VG. Genetic variation reveals a homeotic long noncoding RNA that modulates human hematopoietic stem cells. Cell 2026. PubMed
  • Wan G, Nguyen N, Lu C, Khattab S, Yan B, Amadife M, Leung BW, Chen W, Rajeh A, Tang K, Thang C, Boland G, Reynolds KL, Yu KH, Gusev A, LeBoeuf NR, Kwatra SG, Semenov YR. Systemic Glucocorticoid Immunosuppression and Survival Among Immune Checkpoint Inhibitor Recipients. JAMA Netw Open 2026; 9:e2614323. PubMed
  • Wander SA, Lloyd MR, Keenan JC, Scott EC, Niemierko A, Spring LM, Fell GG, Shin J, Isakoff SJ, Moy B, Ryan L, Padden S, Fisher E, Newton A, Habin KR, Viscosi-Spieler ET, Scarpetti L, Varkaris A, Ellisen LW, Dubash T, Che D, Patel PS, de la Cruz FF, Sutaria DS, Sane RS, Micalizzi DS, Maheswaran S, Haber DA, Juric D, Bardia A. Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer (TAKTIC): a single-centre, open-label, phase 1b trial. Lancet Oncol. 2026; 27:580-591. PubMed
  • Morgans AK, Haresh KP, Jievaltas M, Olmos D, Shore ND, Vjaters E, Xing N, Mohamed AF, Littleton N, Srinivasan S, Verholen F, Saad F. Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2026; 27:614-624. PubMed
  • Valenza C, Zheng Y, Milano M, Berton Giachetti PPM, Trapani D, Giordano E, Guidi L, Boldrini L, Castellano G, Katrini J, Malagutti B, Antonarelli G, Etessami JD, Bianco N, Conforti F, Kirkner GJ, Sangalli C, Dibble KE, Fusco N, Colleoni M, Regan MM, Munzone E, Curigliano G, Partridge AH. Extended Endocrine Therapy and Survival for Breast Cancer Subtypes in Premenopausal Patients. JAMA Netw Open 2026; 9:e2610427. PubMed
  • Cao C, Schmitz KH, Giovannucci EL, Lee IM, Partridge AH, Ligibel JA. Healthy Lifestyle Advice and Practice Among Cancer Survivors in the US. JAMA Oncol 2026. PubMed
  • Chen DD, Zimmer A, Yang DD, Francini E, Patton R, Crowdis J, Chandra P, Bin Riaz I, Hanratty B, Rickles-Young M, Tsuji J, Cibulskis C, Fleharty M, Whelpley B, Reardon B, Park J, Nelson PS, Huang FW, Van Allen EM, Ha G, Choudhury AD. Multi-modal circulating cell-free DNA profiling to predict response to docetaxel in metastatic castration-resistant prostate cancer. NPJ Precis Oncol 2026. PubMed
Hide

Calendar

Training and Education Templates